Skip to main content

Table 1 Clinical situations and the characteristics of the CAR T cells used to treat the 134 CLL patients reported to date

From: State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019

 

Clinical context

CAR T characteristics

Efficacy

Toxicity

Reference/year

Number of CLL patients

Clinical situation

Prior ttmt with ibrutinib

Prior ttmt with venetoclax

TP53 alterations

Complex karyotype

Targeted Ag

Co-stimulation

Cell source

Lymphodepletion

Treatment combination

Responses

CRS all grades N (%)

CRES all grades N (%)

Toxcity-related mortality

[8] / 2011

1

R/R

0

0

1/1

0

CD19

4-1BB

Autologous

P + C

None

CR

1 (100)

0

0

[9] / 2011

8

R/R

0

0

2/8

1/8

CD19

CD28

Autologous

None or C

None

3/8 SD

8 (100)

0

1(13)

[10] / 2011

3

R/R

0

0

2/3

0

CD19

4-1BB

Autologous

B + R or P + C

None

3/3 ORR

2/3 CR

3 (100)

0

0

[11] / 2012

4

R/R

0

0

ND

ND

CD19

CD28

Autologous

F + C

IL2 IV for 5 d

3/4 ORR

1 CR

4 (100)

0

0

[12] / 2013

4

2 Richter

Recurrence after allogeneic treatment

0

0

2/4

ND

CD19

CD28

Allogeneic

None

None

1/4 ORR

1 PR

1 SD

ND

ND

0

[13] / 2015

5

1 Richter

R/R

ND

ND

ND

ND

CD19

CD28

Autologous

F + C

None

5/5 ORR

3 CR 2 PR

3 (60)

1 (20)

0

[14] / 2015

14

R/R

1/14

0

6/14

ND

CD19

4-1BB

Autologous

B or P+ C or F + C

None

8/14 ORR (57%)

4/14 CR (28%)

4/14 PR (28%)

4 MRD neg

9 (64)

5 (36)

0

[15] / 2016

3

R/R

3/3

0

3/3

2/3

CD19

4-1BB

Autologous

ND

Ibrutinib stopped just before leukapheresis

3/3 ORR

1 CR 2 PR

ND

ND

ND

[16] / 2016

5

Recurrence after allogeneic treatment

ND

ND

ND

ND

CD19

CD28

Allogeneic

None

None

2/5 ORR

1 CR

1 PR

4 (80)

0

0

[17] / 2016

2

R/R

0

0

ND

ND

Kappa

CD28

Autologous

None

None

0 ORR

1 SD

ND

ND

ND

[18] / 2017

24

5 Richter

R/R post-ibrutinib

25% post venetoclax

24/24

6/24

23/24

16/24

CD19

4-1BB

Autologous

F + C mostly, or F or C

None

71% ORR

21% CR

43% PR

58% MRD neg

20 (83)

8 (33)

1 (4)

[19] / 2018

8

1st line P + FC

0

0

0

0

CD19

CD28

Autologous

C

None

3/8 ORR (38%)

2/8 CR

4 (50)

0

0

[20] / 2018

19

4 Richter

R/R post-ibrutinib

19/19

11/19

14/19

14/19

CD19

4-1BB

Autologous

F + C

Concomitant ibrutinib

15/18 ORR (83%)

11/13 CR BM with MRD neg

14 (74)

6 (32)

1 (5)

[21] / 2018

19

R/R ×14

+1st line ibrutinib ×5

5 in 1st line

0

11/19

ND

CD19

4-1BB

Autologous

ND“chemotherapy”

Concomitant ibrutinib

10/11 ORR

94 CR BM with

78% MRD neg

18 (95)

5 (26)

0

[22] / 2018

16

R/R post-ibrutinib

16/16

8/16

10/16

8/16

CD19

4-1BB

Autologous

F + C

None

81.3% ORR

7 CR

6 PR

12 (75)

1 (6)

0

  1. The patient from reference [8] is also reported in reference [10] and the 3 patients from the reference [10] are also reported in reference [14]. One patient reported in reference [11] is also reported in reference [13]
  2. R/R relapse/refractory disease, ORR overall response rate, CR complete response, PR partial response, SD stable disease, ND no data, Ttmt treatment, IV intravenous, C cyclophosphamide, B bendamustine, R rituximab, P pentostatin, F fludarabine, CRS cytokine release syndrome, CRES CAR T cell-related encephalopathy syndrome